logo

CUE

Cue Biopharma·NASDAQ
--
--(--)
--
--(--)
4.46 / 10
Netural

CUE's fundamental assessment yields a 4.5/10, indicating moderate financial health. Key positives include strong Revenue-MV (-1.5166) and Profit-MV (0.4634) scores, both in performance group 1 with quality ratings of 2/3 and 2, respectively. The Gross Profit Margin is an impressive 100%, placing it in the top quartile (group 4, score 3). However, Current Assets Turnover (0.2168, group 1, score 0) and Fixed Assets Turnover (1.1331, group 1, score 1/3) ratios are underperforming, dragging overall quality. The PB-ROE factor of 0.3426 situates the stock in group 4 with a quality score of 2/3, historically associated with 10.68% one-month returns. Asset-MV is negative (-0.5007), ranking in group 1 with a historical return of 2.94%. Inventory Turnover is high (47.85), earning a score of 3, while Net Profit / Total Profit is 100% but only scores 0 due to its group placement. This mixed profile suggests selective strengths offset by inefficiencies in asset utilization.

Fundamental(4.46)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-1.52
Score2/3
Weight22.32%
1M Return11.69%
Inventory turnover ratio
Value47.85
Score3/3
Weight8.59%
1M Return5.26%
Gross profit margin (%)
Value100.00
Score3/3
Weight19.65%
1M Return10.80%
Profit-MV
Value0.46
Score2/3
Weight14.64%
1M Return7.79%
PB-ROE
Value0.34
Score2/3
Weight20.56%
1M Return10.68%
Current assets turnover ratio
Value0.22
Score0/3
Weight-2.68%
1M Return-1.88%
Fixed assets turnover ratio
Value1.13
Score1/3
Weight-2.32%
1M Return-1.64%
Asset-MV
Value-0.50
Score0/3
Weight5.00%
1M Return2.94%
Cash-MV
Value-0.07
Score2/3
Weight14.66%
1M Return7.73%
Net profit / Total profit (%)
Value100.00
Score0/3
Weight-0.43%
1M Return-0.30%
Is CUE fundamentally strong?
  • CUE scores 4.46/10 on fundamentals and holds a Fair valuation at present. Backed by its -183.35% ROE, -530.75% net margin, -0.78 P/E ratio, 2.20 P/B ratio, and 54.95% earnings growth, these metrics solidify its Netural investment rating.